{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:04:07Z","timestamp":1789473847384,"version":"build-2803163510"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated substantial weight reduction and cardiovascular benefits in clinical trials. However, its association with clinical outcomes and health care expenditures remains underexplored.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate changes in cardiovascular risk factors and health care expenditures among patients prescribed semaglutide across multicenter cohorts.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study included 23\u202f522 adults (\u226518 years) who received an initial semaglutide prescription between January 1, 2018, and January 1, 2025, at Sentara Healthcare and between January 1, 2018, and May 1, 2025, at Yale New Haven Health System.<\/jats:p><\/jats:sec>Exposure<\/jats:title>The first prescription of semaglutide identified at the ingredient level, stratified by type 2 diabetes status.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes included changes in weight (% baseline), blood pressure (BP), total cholesterol, and hemoglobin A1c<\/jats:sub>. Secondary outcomes assessed health care expenditures using Medicare-based cost estimates. A staggered difference-in-differences design compared outcomes of patients after the first semaglutide prescription with those of patients who had not yet received their prescription during the same period.<\/jats:p><\/jats:sec>Results<\/jats:title>The study cohort included 23\u202f522 patients (mean [SD] age at initiation of semaglutide, 56.2 [12.9] years; 66.7% female; 68.6% with diabetes). In the overall cohort, initiation of semaglutide was significantly associated with a \u22123.8% (95% CI, \u22123.9% to \u22123.7%) reduction in weight at 13 to 24 months, with a \u22125.1% (95% CI, \u22125.5% to \u22124.7%) reduction in weight among patients without diabetes. Significant reductions in diastolic BP (\u22121.5 mm Hg; 95% CI, \u22121.7 to \u22121.4 mm Hg), systolic BP (\u22121.1 mm Hg; 95% CI, \u22121.4 to \u22120.8 mm Hg), and total cholesterol (\u221212.8 mg\/dL; 95% CI, \u221214.3 to \u221211.4 mg\/dL) were also observed. Hemoglobin A1c<\/jats:sub> reductions were greater among patients with diabetes (\u22120.3%; 95% CI, \u22120.3% to \u22120.2%) compared with patients without diabetes (\u22120.1%; 95% CI, \u22120.2% to \u22120.01%). Imputed health care expenditures, excluding the cost of semaglutide, increased by $80 per month (95% CI, $68-$92 per month) during the 13- to 24-month period, which was associated with inpatient stays shifting to more expensive circulatory and metabolic diagnoses.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of adults prescribed semaglutide, initiation was associated with reductions in weight and cardiovascular risk factors but increases in health care expenditures, excluding semaglutide costs. These findings suggest potential clinical benefits in routine practice, while highlighting the need to evaluate the long-term impact of semaglutide on economic outcomes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.26013","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:30:39Z","timestamp":1754667039000},"page":"e2526013","source":"Crossref","is-referenced-by-count":4,"title":["Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide"],"prefix":"10.1001","volume":"8","author":[{"given":"Yuan","family":"Lu","sequence":"first","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"},{"name":"Department of Biomedical Informatics and Data Sciences, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntian","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"},{"name":"Department of Biomedical Informatics and Data Sciences, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tedi","family":"Totojani","sequence":"additional","affiliation":[{"name":"Yale School of Management, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungsoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics and Data Sciences, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John E.","family":"Brush","sequence":"additional","affiliation":[{"name":"Sentara Health Research Center, Sentara Health, Virginia Beach, Virginia"},{"name":"Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[{"name":"Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, Connecticut"},{"name":"Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Abaluck","sequence":"additional","affiliation":[{"name":"Yale School of Management, New Haven, Connecticut"},{"name":"National Bureau of Economic Research, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"5","key":"zoi250733r2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis.","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"zoi250733r3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250733r4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi250733r5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations.","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit Med"},{"issue":"7","key":"zoi250733r6","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/ehjqcco\/qcab070","article-title":"Generalizability of randomized controlled trials in heart failure with reduced ejection fraction.","volume":"8","author":"Lim","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"6","key":"zoi250733r8","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1093\/restud\/rdae007","article-title":"Revisiting event-study designs: robust and efficient estimation.","volume":"91","author":"Borusyak","year":"2024","journal-title":"Rev Econ Stud"},{"issue":"5","key":"zoi250733r9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/dom.15473","article-title":"Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills.","volume":"26","author":"Gasoyan","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"zoi250733r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity.","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi250733r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes.","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"24","key":"zoi250733r12","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250733r13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"zoi250733r14","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","article-title":"Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States.","volume":"14","author":"Weiss","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"zoi250733r15","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1161\/HYPERTENSIONAHA.119.13616","article-title":"National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015.","volume":"74","author":"Chang","year":"2019","journal-title":"Hypertension"},{"key":"zoi250733r16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"issue":"7","key":"zoi250733r17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.18553\/jmcp.2022.28.7.740","article-title":"Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.","volume":"28","author":"Kim","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"issue":"10026","key":"zoi250733r18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(16)30054-X","article-title":"Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants.","volume":"387","author":"Collaboration","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"zoi250733r20","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.amjmed.2005.12.021","article-title":"Approaches to patient education: emphasizing the long-term value of compliance and persistence.","volume":"119","author":"Gold","year":"2006","journal-title":"Am J Med"},{"key":"zoi250733r1","unstructured":"Stierman? B, Afful? J, Carroll? MD, . National Health and Nutrition Examination Survey 2017\u2013March 2020 prepandemic data files\u2014development of files and prevalence estimates for selected health outcomes. National Center for Health Statistics. June 14, 2021. Accessed May 1, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK606854\/"},{"key":"zoi250733r7","unstructured":"Revisions to the standards for the classification of federal data on race and ethnicity. Office of Management and Budget. Federal Register. October 30, 1997;62(210):58781-58790. Accessed July 1, 2025. https:\/\/obamawhitehouse.archives.gov\/omb\/fedreg_1997standards"},{"key":"zoi250733r19","unstructured":"Ward? AS, Tysinger? B, Nguyen? P, Goldman? D, Lakdawalla? D. Benefits of Medicare coverage for weight loss drugs. USC Leonard D. Schaeffer Institute for Public Policy & Government Service. April 18, 2023. Accessed May 1, 2025. https:\/\/schaeffer.usc.edu\/research\/benefits-of-medicare-coverage-for-weight-loss-drugs\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837364\/lu_2025_oi_250733_1753980316.39051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T15:30:40Z","timestamp":1754667040000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26013","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}